Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Exploratory Study of Standard-Dose Ceftazidime-Avibactam PK/PD Target Attainment, Clinical Outcomes, and Induced Resistance in Patients With Hematological Malignancies

NCT07703644 is registered in ClinicalTrials.gov with Sizhou Feng as lead sponsor.

NCT NCT07703644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07703644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Exploratory Study of Standard-Dose Ceftazidime-Avibactam PK/PD Target Attainment, Clinical Outcomes, and Induced Resistance in Patients With Hematological Malignancies
Lead sponsor
Sizhou Feng
Phase
Observational
Overall status
Not yet recruiting
Start date
July 9, 2026
Completion date
July 9, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug resistance, bacterial, gram-negative bacterial infections, hematologic neoplasms, klebsiella pneumoniae infections, pseudomonas aeruginosa infection